ClinicalTrials.gg
Not yet recruitingNCT07941674KB12Updated Nov 17, 2026

Persistent Vitamin B12 Hypervitaminemia: Identification of Biomarkers for the Early Detection of Solid Cancers

An interventional study of Blood-Based Vitamin B12 Biomarker Panel in Hypercobalaminemia and Neoplasms, sponsored by University Hospital, Angers. Not yet recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Diagnostic

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Elevated blood levels of vitamin B12 are sometimes discovered unexpectedly during routine blood tests. Persistently elevated vitamin B12 levels can occur for several reasons, including liver disease, kidney disease, blood disorders, vitamin B12 supplementation, and certain solid cancers. However, a high vitamin B12 level alone does not indicate whether cancer is present, and it remains unclear which patients should undergo further investigations.

The KB12 study aims to determine whether measuring specific blood markers involved in vitamin B12 transport and uptake can help distinguish elevated vitamin B12 levels associated with solid cancers from those related to other conditions. Researchers hypothesize that these markers may differ according to the underlying cause of the elevated vitamin B12.

In this multicenter study, participants with persistently elevated vitamin B12 levels will provide a blood sample for laboratory analysis. Researchers will compare the levels of these markers between participants with solid cancers and those with other identified causes of elevated vitamin B12. Participants will also be contacted by telephone approximately one year later to check for any newly diagnosed conditions. Participation will not change their usual medical care.

The results may help develop more targeted approaches to investigating persistently elevated vitamin B12 levels, with the long-term goal of improving early cancer detection while avoiding unnecessary examinations.

Read the detailed description

Persistent elevation of total serum vitamin B12 (tB12) has been associated with solid cancers, particularly when confirmed by repeated measurements at least four weeks apart. However, hypercobalaminemia is nonspecific and may also result from myeloid disorders, chronic liver disease, severe chronic kidney disease, or excessive vitamin B12 supplementation. There is currently no established diagnostic strategy to identify which patients with persistent hypercobalaminemia would benefit most from further investigations for an underlying solid malignancy.

Routine measurement of tB12 does not distinguish the different biological components involved in vitamin B12 transport and cellular uptake. The KB12 study investigates the hypothesis that one or a combination of these components may be more specifically associated with solid cancers. The candidate biomarkers include transcobalamin I (TCI), transcobalamin II (TCII), holotranscobalamin (holoTC), and circulating CD320 (CD320c), a circulating form of the cellular receptor involved in vitamin B12 uptake. Differences in their circulating levels may reflect distinct pathophysiological mechanisms underlying hypercobalaminemia and could potentially improve the identification of patients requiring further oncological assessment.

KB12 is a prospective, multicenter, comparative cohort study conducted across three centers in France. Participants are identified during routine clinical care following the detection of elevated tB12 levels. Persistence of hypercobalaminemia is confirmed by repeated testing performed as part of standard care. Participants are classified into two groups according to the clinically established cause of hypercobalaminemia: solid cancer (CANCER group) or another recognized etiology (OTHER CAUSES group).

At the inclusion visit, an additional blood sample (up to 10 mL) is collected for research purposes. Plasma and serum samples are prepared, aliquoted, and stored frozen before transfer to the Biological Resource Center of Angers University Hospital. Biomarker measurements are subsequently performed centrally using stored samples.

A telephone follow-up is conducted approximately 12 months after inclusion to identify any newly diagnosed condition potentially associated with elevated vitamin B12, particularly solid cancer. Follow-up information will be used to support the interpretation of the findings without changing the initial group classification.

All participants continue to receive standard medical care, with no changes in diagnostic or therapeutic management related to study participation. No experimental treatment is administered.

This exploratory study is intended to identify candidate biomarkers associated with solid cancers in patients with persistent hypercobalaminemia and to provide a basis for subsequent validation studies before potential clinical implementation.

02

Conditions studied

  • Hypercobalaminemia
  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University Hospital, Angers is the lead sponsor of 480 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Affiliation to a French social security system.
  • Persistent hypercobalaminemia, defined as total serum vitamin B12 >1,000 ng/L on at least two measurements performed at least 4 weeks apart.
  • A single identified cause of persistent hypercobalaminemia among the following:

    • Myeloid , diagnosed according to current international classifications (WHO 2022 and/or International Consensus Classification 2022).
    • Chronic liver disease with cirrhosis, established according to current international recommendations using non-invasive biological and imaging assessments, with histological confirmation if necessary.
    • Severe chronic kidney disease, defined as an estimated \<30 mL/min/1.73 m² persisting for more than 3 months.
    • Excessive exogenous vitamin B12 supplementation, defined as intramuscular administration ≥1,000 µg/month and/or oral supplementation ≥3,000 µg/week, in the absence of pernicious anemia.
    • confirmed invasive solid cancer, with at least locally advanced disease (local extension or regional lymph node involvement).
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Presence of multiple concurrent causes of hypercobalaminemia, or insufficient clinical data to exclude an additional underlying cause.
  • Pregnancy, breastfeeding, or childbirth.
  • Deprivation of liberty by judicial or administrative decision.
  • Involuntary psychiatric treatment.
  • Persons under legal protection.
  • Inability to provide .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Persistent elevated B12

    All participants with persistent hypercobalaminemia undergo the same study-specific blood sampling procedure for the measurement of vitamin B12-related biomarkers. Participants are classified into two predefined subgroups according to the underlying cause of hypercobalaminemia: solid cancer (CANCER group) or other identified causes (OTHER CAUSES group). No treatment or diagnostic procedure is assigned differently between the two subgroups.

    Diagnostic Test: Blood-Based Vitamin B12 Biomarker Panel

Interventions

  • Diagnostic testBlood-Based Vitamin B12 Biomarker Panel

    A single blood sample (up to 10 mL, collected after at least 3 hours of fasting) is obtained at study inclusion using one EDTA tube and one serum tube. Plasma and serum are separated, aliquoted, and stored frozen before centralized laboratory analysis. The following vitamin B12-related biomarkers are measured: transcobalamin I (TCI), transcobalamin II (TCII), holotranscobalamin (holoTC), and circulating CD320 (CD320c). Biomarker measurements are performed for research purposes only and do not influence participants' usual medical care.

06

What researchers measure

Primary outcomes

  1. Between-group differences in vitamin B12-related biomarker concentrations

    Time frame: At inclusion (baseline blood sample)

Secondary outcomes

  1. Area under the receiver operating characteristic curve (AUC) for solid cancer detection

    Time frame: At inclusion (baseline blood sample)

  2. Cutoff values of vitamin B12-related biomarkers (Optimal diagnostic)

    Time frame: At inclusion (baseline blood sample)

  3. Sensitivity

    Time frame: At inclusion (baseline blood sample)

  4. specificity

    Time frame: At inclusion (baseline blood sample)

  5. positive predictive value of vitamin B12-related biomarkers

    Time frame: At inclusion (baseline blood sample)

  6. negative predictive value of vitamin B12-related biomarkers

    Time frame: At inclusion (baseline blood sample)

  7. Association between vitamin B12-related biomarker concentrations and certain tumor characteristics

    Mesure of vitamin B12-related biomarker concentrations

    Time frame: At inclusion (baseline blood sample)

  8. Association between vitamin B12-related biomarker concentrations and certain tumor characteristics

    metastatic or non-metastatic tumor

    Time frame: At inclusion (baseline blood sample)

  9. Association between vitamin B12-related biomarker concentrations and certain tumor characteristics

    tumor location

    Time frame: At inclusion (baseline blood sample)

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared upon reasonable request. Only de-identified data will be shared. Any data collected during the study may be shared. The protocol will be shared initially. Other documents may be shared at a later date upon request (e.g., the CRF to allow a collaborator to select the data they wish to access). The recipients of the data will be researchers. The data will be available for any purpose deemed relevant by the study investigator, based on a protocol provided by the requester, after verification of the obtaining of regulatory approvals, including the favorable opinion of an ethics committee.

Supporting information: Study protocol

Time frame: The data will be shared after signing a negotiated data transfer agreement ( data access agreement), for the duration specified in the agreement.

Access criteria: The data will be made available via secure transfer (sharing platform approved by the university hospital: BlueFiles or Oodrive).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Feb 2030, 36 months later.

Of 1,986 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 36 months is above that.

Counting every sponsor, half of 2,061 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Feb 1, 2030
CompletionEst.
Mar 1, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941674
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Feb 1, 2030 (estimated)
Completion
Mar 1, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Valentin Dr ACOMBE
Contact
valentin.lacombe@ch-hautanjou.fr
+33243707342

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion